5/8
07:08 am
aldx
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease [Yahoo! Finance]
Low
Report
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease [Yahoo! Finance]
5/8
07:00 am
aldx
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
Low
Report
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
5/7
12:32 am
aldx
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
5/6
08:06 am
aldx
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
5/6
08:05 am
aldx
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
Low
Report
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
4/25
07:00 am
aldx
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Medium
Report
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
4/22
11:51 am
aldx
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Low
Report
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
4/18
07:00 am
aldx
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Medium
Report
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
4/6
08:10 am
aldx
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why [Yahoo! Finance]
High
Report
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why [Yahoo! Finance]
4/3
08:06 am
aldx
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
High
Report
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
4/3
07:44 am
aldx
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner [Yahoo! Finance]
High
Report
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner [Yahoo! Finance]
4/2
09:01 am
aldx
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
3/28
07:09 am
aldx
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease [Yahoo! Finance]
Medium
Report
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease [Yahoo! Finance]
3/28
07:00 am
aldx
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
Medium
Report
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
3/6
11:35 am
aldx
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now [Yahoo! Finance]
Low
Report
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now [Yahoo! Finance]
3/1
11:10 am
aldx
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics [Yahoo! Finance]
Low
Report
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics [Yahoo! Finance]
2/22
07:57 am
aldx
Institutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the company [Yahoo! Finance]
Medium
Report
Institutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the company [Yahoo! Finance]
2/9
09:00 pm
aldx
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Aldeyra Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm